{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011297","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.838469+00:00","generated_at":"2026-05-17T13:53:28.687188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProMIS Neurosciences Q2 net loss $10.1M; PRECISE-AD enrollment >50%, no ARIA; raised $21.6M in July","bullets":["Net loss $10.1M for Q2 2025 vs $2.6M a year ago; R&D spend $8.7M on PRECISE-AD trial.","Cash $4.5M at June 30; raised $21.6M gross proceeds in July via offerings and warrant exercises.","PRECISE-AD Phase 1b: over 50% of 128 patients enrolled; no ARIA or dropouts to date.","FDA granted Fast Track Designation for PMN310 in Alzheimer's disease in July 2025.","Company expects blinded interim results in 2Q 2026, final topline in 4Q 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011297","json":"https://secwatch.observer/filing/0001558370-25-011297.json","markdown":"https://secwatch.observer/filing/0001558370-25-011297.md","text":"https://secwatch.observer/filing/0001558370-25-011297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/0001558370-25-011297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/pmn-20250813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:53:28.687188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}